ArticleInternational journal of mental health systems2013
An investigation of economic costs of schizophrenia in two areas of China.
Article in International journal of mental health systems, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of Schizophrenia.Frontiers in public health · 2021Pooled it
- Feasibility and preliminary effectiveness of electronic medication monitoring system to improve antipsychotic adherence: a type 1 effectiveness-implementation hybrid pilot study.BMC psychiatry · 2026Trial
- Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study.BMC psychiatry · 2014Trial
- Clinical Practice Recommendations for Switching from Once-Monthly to Longer-Interval Paliperidone Palmitate Injectable in Schizophrenia Patients: A Modified Delphi Study in China.Neuropsychiatric disease and treatment · 2026Article
- A study on the changing trend and influencing factors of hospitalization costs of schizophrenia in economically underdeveloped areas of China.Schizophrenia (Heidelberg, Germany) · 2023Article
- Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.Frontiers in public health · 2022Article
- Experiences of Family Burden in Caring for the Severely Mentally Ill in a Foreign Land: A Qualitative Study of Chinese Immigrant Families in Toronto, Canada.Transcultural psychiatry · 2021Article
- The cost of obsessive-compulsive disorder (OCD) in China: a multi-center cross-sectional survey based on hospitals.General psychiatry · 2021Article
- The psychosis analysis in real-world on a cohort of large-scale patients with schizophrenia.BMC medical informatics and decision making · 2020Article
- Household economic burden and outcomes of patients with schizophrenia after being unlocked and treated in rural China.Epidemiology and psychiatric sciences · 2019Article
- Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia.Neuropsychiatric disease and treatment · 2019Article
- Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China.General psychiatry · 2018Article
- Direct medical costs for patients with schizophrenia: a 4-year cohort study from health insurance claims data in Guangzhou city, Southern China.International journal of mental health systems · 2018Article
- Economic cost and quality of life of family caregivers of schizophrenic patients attending psychiatric hospitals in Ghana.BMC health services research · 2017Article
- The Cost of Relapse in Schizophrenia.PharmacoEconomics · 2017Review
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Therapeutics and clinical risk management · 2017Review
- The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel.The Psychiatric quarterly · 2016Article
- Comparison of burden among family members of patients diagnosed with schizophrenia and bipolar disorder in a large acute psychiatric hospital in China.BMC psychiatry · 2016Article
- Global economic burden of schizophrenia: a systematic review.Neuropsychiatric disease and treatment · 2016Review
- Transition to Psychosis: Evaluation of the First-Degree Relatives of Patients with Schizophrenia .Iranian journal of psychiatry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a severe psychotic disorder characterized by significant disturbances in thinking, perception, emotions and behavior. Even if it is not a very frequent disorder, but it is the most burdensome and costly illnesses worldwide. The total population was approximate 1.3 billion and there are approximate 8 million schizophrenic patients in China. Despite the wide-ranging financial and social burdens associated with schizophrenia, but there have been few cost-of-illness studies of this illness in China.
objectiveTo evaluate the economic cost of schizophrenic patients in China. METHODOLOGY: 356 schizophrenic patients who met with DSM-IV criteria were enrolled and investigated with the Economic Burden Questionnaire(EBQ), 299 schizophrenic patients completed the study for 12 months. All the data were combined and classified by researcher. EBQ include all kinds of cost such as direct cost, indirect cost and total cost as well. It was filled in by patients and their close caregivers. Comparison of cost was made between not only out-patients and in-patients but also urban patients and rural patients. Multiple stepwise regression analysis was made to identify the main influence factors of total cost.
results(i) The per case per annum total costs, direct costs and indirect costs of schizophrenia amounted to US$2586.21, US$862.81(33.4%) and US$1723.40(66.6%) respectively. The per case total cost, direct cost and direct medical cost of in-patients were more higher than out-patients (P < 0.05). (ii) There was significant difference in per case per annum total cost, direct cost, direct medical cost, cost due to lost working-days and disability between urban and rural schizophrenic patients (P < 0.05), the former is higher than the latter. (iii) The results of multivariate stepwise regression analysis show that five variables were significantly correlated with higher cost: professional status(cadre), diagnostic subtype(residual schizophrenia), urban or rural patients(urban patients), in-patients or out-patients(in-patients) and researcher centre(southern center). The standardized regression coefficient were 0.308, 0.218, 0.212, 0.156 and 0.149 respectively, the correlation of determination R square was 0.2741, F = 15.651, P < 0.0000. These characteristics explain 27.41% of the variability in the total cost.
conclusion(i) Economic cost of schizophrenia were serious, we must pay close attention to it. (ii) The indirect cost are the majority of the total cost. The cost of urban patients are more higher than the cost of rural patients, the cost of in-patients are more higher than the cost of out-patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.